

[Home](#) > [Journal](#) > [Chemistry & Materials Science](#) | [Medicine & Healthcare](#) > [MC](#)[Indexing](#) [View Papers](#) [Aims & Scope](#) [Editorial Board](#) [Guideline](#) [Article Processing Charges](#)

MC > Vol.1 No.2, October 2012

OPEN ACCESS

New antimyeloma drugs in spinal cord infiltration for multiple myeloma. Determination of lenalidomide in cerebrospinal fluid with ultrasensitive high-performance liquid chromatography

PDF (Size: 43KB) PP. 11-13 DOI: 10.4236/mc.2012.12003

Author(s)

Inmaculada Rapado, Juan José Lahuerta, Laura Montejano, María Ángeles Montalbán, Laura Pares, Joaquín Martínez- López

ABSTRACT

A 64-year-old woman with IgA kappa multiple myeloma was treated with thalidomide-dexa- methasone. Due to progression of the disease, bortezomib, doxorubicin and dexamethasone were administered, followed by autologous stem cell transplantation. Although near-complete remission was achieved, 5 months later, neuro- logical symptoms appeared and the patient was diagnosed with multiple myeloma with cells in- filtrating the spinal cord. Bis-chloronitrosourea, bortezomib and lenalidomide were then administered and although the patient remained neu- rologically asymptomatic, she died 3 months later because of disease progression. Lena- lidomide entered into the cerebrospinal fluid (confirmed by ultrasensitive high-performance liquid chromatography), although did not im- prove the poor prognosis of multiple myeloma involving the central nervous system.

KEYWORDS

Lenalidomide; Multiple Myeloma; Spinal Cord Infiltration; High-Performance Liquid Chromatography

Cite this paper

Rapado, I. , Lahuerta, J. , Montejano, L. , Montalbán, M. , Pares, L. and López, J. (2012) New antimyeloma drugs in spinal cord infiltration for multiple myeloma. Determination of lenalidomide in cerebrospinal fluid with ultrasensitive high-performance liquid chromatography. *Modern Chemotherapy*, 1, 11-13. doi: 10.4236/mc.2012.12003.

References

- [1] Fassas, A.B., Muwalla, F., Berryman, T., Benramdane, R., Joseph, L., Anaissie, E., et al. (2002) Myeloma of the central nervous system: Association with high-risk chromosomal abnormalities, plasmablastic morphology, and extramedullary manifestations. *British Journal of Haematology*, 117, 103-108. doi:10.1046/j.1365-2141.2002.03401.x
- [2] Chang, H., Bartlett, S.E., Patterson, B., Chen, I.C. and Long, Y.Q. (2005) The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. *British Journal of Haematology*, 129, 539-541. doi:10.1111/j.1365-2141.2005.05493.x
- [3] Nieuwenhuizen, L. and Biesma, D.H. (2008) Central nervous system myelomatosis: Review of the literature. *European Journal of Haematology*, 80, 1-9.
- [4] Tsenova, L., Mangaliso, B., Muller, G., Chen, Y., Freedman, V.H., Stirling, D., et al. (2002) Use of IMDi3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. *Antimicrobial Agents and Chemotherapy*, 46, 1887-1895. doi:10.1128/AAC.46.6.1887-1895.2002
- [5] Varettoni, M., Corso, A., Zappasodi, P., Calliada, F., Castagnola, C., Mangiacavalli, S., et al. (2008) Infiltration of the spinal cord in a patient with multiple myeloma. *Journal of Clinical Oncology*, 26, 4207-4209.
- [6] Dimopoulos, M.A. and Kastiris, E. The role of novel drugs in multiple myeloma. *Annals of Oncology*,

[MC Subscription](#)[Most popular papers in MC](#)[About MC News](#)[Frequently Asked Questions](#)[Recommend to Peers](#)[Recommend to Library](#)[Contact Us](#)

Downloads: 485

Visits: 10,933

[Sponsors >>](#)

- [7] Serefhanoglu, S., Haznedaroglu, I.C., Goker, H., Buyukasik, Y. and Ozcebe, O.I. (2009) Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma. *Onkologie*, 32, 662-664.
- [8] Colagrande, M., Di Ianni, M., Ciurnelli, R., Gallucci, M., Mariani, G. and Tabilio, A. (2007) Striking response to intrathecal liposomal cytarabine in a patient with meningeal myelomatosis. *British Journal of Haematology*, 138, 812- 823. doi:10.1111/j.1365-2141.2007.06712.x
- [9] Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. *Blood*, 100, 3063-3067. doi: 10.1182/blood-2002-03-0996
- [10] Dahut, W.L., Aragon-Ching, J.B., Woo, S., Tohnya, T.M., Gulley, J.L., Arlen, P.M., et al. (2009) Phase I study of oral lenalidomide in patients with refractory metastatic cancer. *The Journal of Clinical Pharmacology*, 49, 650- 660. doi:10.1177/0091270009335001